After Hours: HeartBeam (BEAT) NASDAQ $1.35 (-8.78%) pre-Mar 12 earnings: watch guidance

BEAT stock opened a sharp after-hours focus at $1.35, down -8.78%, as investors position ahead of HeartBeam, Inc.’s (BEAT) March 12, 2026 earnings release. Trading volume surged to 32,574,883 shares today, far above the 7,000,000 average, signaling heightened liquidity risk and interest. We set out the key metrics, analyst signals, and what to watch in the NASDAQ-listed HeartBeam (United States, USD) report that could reshape the short-term outlook.

Earnings timing and market context for BEAT stock

HeartBeam (BEAT) reports earnings on 2026-03-12 after-market, creating a clear catalyst. The market has priced heightened risk: the stock closed today at $1.35 on NASDAQ with intraday range $1.34–$1.65. Volume spiked to 32,574,883 versus average 6,961,762, indicating heavy trading ahead of the release. Sector peers in Healthcare have shown mixed medtech returns, increasing the importance of clear guidance and adoption signals from management.

Financial snapshot: key metrics and valuation

HeartBeam shows constrained fundamentals. Reported EPS is -0.66 and trailing PE is -2.05, reflecting negative earnings. Market cap stands near 46,498,806.00 USD and shares outstanding equal 34,443,560. The 50-day average price is 1.80 and 200-day average is 1.56, placing current price below the 50-day average but close to the 200-day mean. Current ratio is 0.86, cash per share 0.05, and book value per share 0.01, which highlight tight liquidity and limited tangible equity.

BEAT stock technicals and trading signals

Technicals show tepid momentum. RSI is 42.46, MACD histogram is 0.02, and ADX 15.38 indicates no clear trend. Bollinger Bands range 1.26–1.58, and ATR is 0.16, pointing to moderate intraday swings. On‑balance volume and relative volume show heavy participation today, meaning earnings could trigger amplified moves in either direction. Traders should watch a break under $1.34 or a reclaim of $1.58 for short-term direction.

Meyka AI rating and analyst consensus for BEAT stock

Meyka AI rates BEAT with a score of 68.14 out of 100 — Grade: B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Sell-side activity shows 2 Strong Buy and 5 Buy recommendations and a consensus score of 4.00, but institutional caution follows limited revenue history and negative profitability.

Catalysts, risks, and strategic developments for BEAT stock

Near-term catalysts include the March 12 earnings call and upcoming investor events in March. Recent corporate news lists a strategic AI collaboration with Mount Sinai and multiple conference presentations, which could support commercial credibility. Key risks are minimal revenue disclosure, negative cash flow per share -0.45, potential delisting notices reported by some outlets, and a high price‑to‑book ratio ~124.12, which raises valuation sensitivity to execution.

BEAT stock forecast and price-target scenarios

Meyka AI’s forecast model projects a 12‑month target of 2.13 USD, with a monthly view of 1.15 USD and quarterly 1.04 USD. Against the current 1.35 USD, the 12‑month projection implies an upside of 42.63%. We outline three scenarios: Bear 0.80 USD if guidance weakens, Base 1.35 USD if results match expectations, and Bull 2.50 USD if adoption and AI partnerships accelerate. Forecasts are model-based projections and not guarantees.

Final Thoughts

Key takeaways for BEAT stock focus on earnings and execution. HeartBeam (BEAT) trades at 1.35 USD after hours on NASDAQ with heavy volume, setting the stage for material post‑earnings moves. The company shows negative EPS -0.66 and tight liquidity, which raises sensitivity to guidance. Meyka AI’s forecast model projects 2.13 USD in 12 months, implying ~42.63% upside vs. today, but that view assumes commercial traction from recent FDA-clearance momentum and the Mount Sinai AI collaboration. Our Meyka AI grade (B, HOLD) balances upside potential with execution risk. For active traders, watch intraday support at 1.34 USD and resistance near 1.58 USD. Long-term investors should demand clearer revenue trends and margin improvement before upgrading exposure. For more detail and ongoing updates, see the company releases and our internal BEAT stock page at Meyka BEAT page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.